RPL19

Across TCGA pan-cancer cohorts, RPL19 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of RPL19’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where RPL19 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types RPL19 is over-expressed in tumor.

CCRCC, COAD, and PDAC are the cancer types where RPL19 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL19 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	III,IV	+0.840	<.001	12	view →
COAD	Male	III,IV	+0.483	<.001	9	view →
PDAC	Male	All	+0.656	<.001	6	view →
LUAD	Male	All	+0.176	<.001	2	view →
HNSC	All	All	+0.131	.034	2	view →
LSCC	All	All	+0.083	.045	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

RPL19–CCRCC

Open the CCRCC breakdown →